
    
      The treatment period is composed of a 24-week double-blind period (Phase A) and a 28-week
      open-label period (Phase B). During Phase A, participants will received either omarigliptin
      25 mg or a matching placebo. During Phase, B all participants will receive omarigliptin 25
      mg. All participants will remain on a stable dose and administration of a single oral
      antihyperglycemic basal medication.
    
  